ArticleAnnals of surgical oncology2025
Utility of Surgical Axillary Staging in Microinvasive Ductal Carcinoma In Situ: A National Cancer Database Analysis.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Complete disappearance of ductal carcinomaAnnals of medicine and surgery (2012) · 2026Article
- Refining Sentinel Lymph Node Biopsy Decisions for Clinically Node-Negative Microinvasive DCIS.The breast journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical axillary staging (ASx) of patients with microinvasive ductal carcinoma in situ (cT1mi) is debated due to the low occurrence of nodal metastasis. This study aimed to assess the utility of surgical axillary staging for clinically node-negative (cN0) T1mi breast cancer patients.
methodsThis retrospective cohort study analyzed data from the National Cancer Database (NCDB) to investigate the axillary status of patients with cT1mi breast cancer between 2012 and 2019. Patient demographics, clinical characteristics, treatment methods, and pathologic findings were collected.
resultsOf 10,843 patients, 9220 (85%) underwent ASx, whereas 1623 (15%) did not. Of the 4190 patients who underwent mastectomy, 244 (6%) did not undergo ASx, whereas 3946 (94%) did, 373 (9%) of whom were pN+. Of the 9069 patients who underwent ASx and had known nodal status, 8512 (94%) were pN- and 557 (6%) were pN+. The factors independently associated with increased odds of having positive nodes were younger age (odds ratio [OR], 1.02; 95% confidence interval [CI], 1.01-1.03; p < 0.001), black race (OR, 1.51; 95% CI, 1.12-2.10; p = 0.007), lymphovascular invasion (OR, 13.72; 95% CI, 10.25-18.36; p < 0.001), and mastectomy (OR, 1.98; 95% CI, 1.57-2.51; p < 0.001). Among the pN+ patients, only 64 (1%) had ≥3 positive nodes and would require axillary lymph node dissection (ALND).
conclusionSurgical axillary staging is commonly performed for patients with cT1mi breast cancer despite the pN- status of most and the disproportionate morbidity associated with ASx. Identifying factors that predict a higher likelihood of pN+ status could allow for personalized surgical approaches, reducing unnecessary ASx for many patients.
Indexed as
Identifiers
40205150What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.